Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Metastatic non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) may suffer from heavy side effects, and not all patients benefit from the treatment. Therefore, it is crucial to gain knowledge about possible (bio-)markers for response to ICIs. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiltbrunner, Stefanie, Spohn, Meta-Lina, Wechsler, Ramona, Akhoundova, Dilara, Bankel, Lorenz, Kasser, Sabrina, Bihr, Svenja, Britschgi, Christian, Maathuis, Marloes H., Curioni-Fontecedro, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750624/
https://www.ncbi.nlm.nih.gov/pubmed/35008239
http://dx.doi.org/10.3390/cancers14010075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750624/
https://www.ncbi.nlm.nih.gov/pubmed/35008239
http://dx.doi.org/10.3390/cancers14010075

Ejemplares similares